-- （見出しと冒頭段落に最新の株価動向を追記しました。） Twilio（TWLO）の株価は、同社が予想を上回る第1四半期決算を発表した翌日の金曜午後の取引で約22%急騰しました。 同社は木曜遅くに、第1四半期の調整後1株当たり利益（EPS）が前年同期の1.14ドルから1.50ドルに増加したと発表しました。 FactSetが調査したアナリストは1.27ドルを予想していました。 3月31日締めの第1四半期の売上高は14億1000万ドルで、前年同期の11億7000万ドルから増加しました。 FactSetが調査したアナリストは13億4000万ドルを予想していました。 第2四半期について、同社は調整後EPSを1.27ドルから1.32ドル、売上高を14億2000万ドルから14億3000万ドルと予想しています。アナリストはそれぞれ1.29ドルと13億9000万ドルを予想しています。
Price: $180.02, Change: $+31.96, Percent Change: +21.59%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our 12-month target by CAD35 to CAD370, as we value AEM using an EV/EBITDA of 8.4x applied to our 2027 EBITDA estimate, in line with AEM's three-year average forward EV/EBITDA of 8.4x and a premium to the peers' average of 5.3x. We increase our EPS estimates: 2026 by USD1.13 to USD14.65 and 2027 by USD2.71 to USD17.58. AEM delivered a strong Q1 with record operating margins driven by elevated gold prices and disciplined cost control. 2026 production guidance remains 3.3-3.5 million ounces with costs tracking to plan. AEM's balance sheet remains strong with $2.9B in net cash, supporting an industry-leading growth pipeline targeting 20%-30% production growth over the next decade through projects at Detour underground, Canadian Malartic expansion, Hope Bay, and Upper Beaver. The proposed Finland consolidation adds a potential 500k oz platform. Management plans to return 40% of free cash flow via dividends and an expanded $2B buyback program, while simultaneously funding high-return growth projects.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our 12-month target by $6.50 to $7.50, on an EV/EBITDA of 5.5x our 2026 EBITDA estimate, below O-I's one-year average of 5.6x. We decrease our 2026 EPS by $0.58 to $1.25 and 2027 by $0.40 to $1.95. O-I's Fit to Win program achieved $35M in net savings during Q1 and is 50% of the way to its goal of $750M in benefits, a highlight of the quarter. O-I secured 15 new accounts in the quarter that should drive 2H 2026 volume 1.5% higher. We note that volumes were down 8% Y/Y; this trend improved in March, with volumes down only 2%. Management noted that the European segment was the primary driver of poor results, with a $68M decrease from the prior year attributable to softer demand and intense competition in the Southern European wine market. Inflation risks from conflicts in the Middle East are a major risk, potentially adding $75M-$100M in costs if prices remain elevated. We currently see 2027 EBITDA as flat vs. 2025 ($1.23B), but this view could improve if energy prices decrease in 2H 2026.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.